Contraception
Volume 79, Issue 4 , Pages 259-271 , April 2009

Misoprostol for termination of pregnancy with intrauterine fetal demise in the second and third trimester of pregnancy — a systematic review

  • Rodolfo Gómez Ponce de León

      Affiliations

    • IPAS and School of Public Health, University of North Carolina at Chapel Hill, NC 28516, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 919 9605573; fax: +1 919 9297687.
    • ,
  • Deborah A. Wing

      Affiliations

    • Division of Maternal–Fetal Medicine, Department of Obstetrics–Gynecology, University of California, Irvine, CA 92868, USA

Received 17 July 2008 ,Revised 13 October 2008 ,Accepted 15 October 2008.

References 

  1. Eng NS, Guan AC. Comparative study of intravaginal misoprostol with gemeprost as an abortifacient in second trimester missed abortion. Aust N Z J Obstet Gynaecol. 1997;37:331–334
  2. Weiner CP. Fetal death. In:  James DK,  Steer PJ,  Weiner CP,  Gonik B editor. High risk pregnancy management options. 2nd ed.. London: WB Saunders; 1999;p. 323–326
  3. Winikoff B, Ellerston C, Clark S. Analysis of failure in medical abortion. Contraception. 1996;54:323–327
  4. Grimes DA. Medical abortion in early pregnancy: a review of the evidence. Obstet Gynecol. 1997;89:790–796
  5. Slade P, Heke S, Fletcher J, Stewart P. A comparison of medical and surgical termination of pregnancy: choice, emotional impact and satisfaction with care. Br J Obstet Gynaecol. 1998;105:1288–1295
  6. Costa SH, Vessey MP. Misoprostol and illegal abortion in Rio de Janeiro, Brazil. Lancet. 1993;342:1258–1261
  7. Senior J, Marshall K, Sangha R, Clayton JK. In vitro characterization of prostanoid receptors on human myometrium at term pregnancy. Br J Pharmacol. 1993 Feb;108(2):501–506
  8. Zieman M, Frong SK, Benowitz NL, Banskter D, Darney PD. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol. 1997;90:88–92
  9. Tang OS, Schweer H, Seyberth HW, Lee SW, Ho PC. Pharmacokinetics of different routes of administration of misoprostol. Human Reprod. 2002;17:332–336
  10. Tang OS, Gemzell Danielsson K, Ho PC. Misoprostol: Pharmacokinetic profiles, effects on the uterus and side effects. Int J Gynaecol Obstet. 2007;99:160–167
  11. In: Royal College of Obstetricians and Gynaecologists  editors. Medical methods of abortion. The care of women requesting induced abortion. Evidence-Based Clinical Guideline Number 7. London: RCOG Press; 2004;p. 52–56
  12. Gomez Ponce de Leon R, Wing D, Fiala C. Misoprostol for intrauterine fetal death. Int J Gynaecol Obstet. 2007;99:190–193
  13. Henry AM, Haukkamaa M. Comparison of vaginal misoprostol and gemeprost as pre-treatment in first trimester pregnancy interruption. Br J Obstet Gynaecol. 1999;106:540–543
  14. Dickinson JE, Godfrey M, Evans SF. Efficacy of intravaginal misoprostol in second-trimester pregnancy termination: a randomized controlled trial. J Matern Fetal Med. 1998;7:115–119
  15. Bamigboye AA, Merrell DA, Hofmeyr GJ, Mitchell R. Randomized comparison of rectal misoprostol with Syntometrine for management of third stage of labor. Acta Obstet Gynecol Scand. 1998;77:178–181
  16. Diab KM, Ramy AR, Yehia MA. The use of rectal misoprostol as active pharmacological management of the third stage of labor. J Obstet Gynaecol Res. 1999;25:327–332
  17. Dodd J, Crowther CA, Dodd JM, Crowther CA. Misoprostol for induction of labour to terminate pregnancy in the second or third trimester for women with a fetal anomaly or after intrauterine fetal death. Cochrane Database Syst Rev. 2004;(3):CD004901
  18. Dodd JM, Crowther CA. Misoprostol versus cervagem for the induction of labour to terminate pregnancy in the second and third trimester: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2006;125:3–8
  19. Hofmeyr GJ, Gulmezoglu AM. Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev. 2003;(1):CD000941;[Review]
  20. Danielsson KG, Marions L, Rodriguez A, Spur BW, Wong PY, Bygdeman M. Comparison between oral and vaginal administration of misoprostol on uterine contractility. Obstet Gynecol. 1999;93:275–280
  21. Meckstroth KR, Whitaker AK, Bertisch S, Goldberg AB, Darney PD. Misoprostol administered by epithelial routes: Drug absorption and uterine response. Obstet Gynecol. 2006;108(3 Pt 1):582–590
  22. In:  Higgins JPT,  Green S editor. Cochrane handbook for systematic reviews of interventions. 2008;Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008 www.cochrane-handbook.org
  23. Bebbington MW, Kent N, Lim K, et al. A randomized controlled trial comparing two protocols for the use of misoprostol in midtrimester pregnancy termination. Am J Obstet Gynecol. 2002;187:853–857
  24. Bugalho A, Bique C, Machungo F, Faundes A. Induction of labor with intravaginal misoprostol in intrauterine fetal death. Am J Obstet Gynecol. 1994;171(2):538–541
  25. Bugalho A, Bique C, Machungo F, Bergstrom S. Vaginal misoprostol as an alternative to oxytocin for induction of labor in women with late fetal death. Acta Obstet Gynecol Scand. 1995;74:194–195
  26. Cohen Blumenthal F, Medina C. Use of misoprostol for induction of second-trimester abortion in patients with previous cesarean delivery. Obstet Gynecol. 2001;97(4 Suppl):68S
  27. de Heus R, Graziosi GCM, Christiaens GCML, Bruinse HW, Mol BWJ. Medical management for termination of second and third trimester pregnancies: a comparison of strategies. Eur J Obstet Gynecol Reprod Biol. 2004;116:16–21
  28. Dickinson JE. Misoprostol for second-trimester pregnancy termination in women with a prior cesarean delivery. Obstet Gynecol. 2005;105(2):352–356
  29. Feldman DM, Borgida AF, Rodis JF, Leo MV, Campbell WA. A randomized comparison of two regimens of misoprostol for second-trimester pregnancy termination. Am J Obstet Gynecol. 2003;189:710–713
  30. Gonzalez JA, Carlan SJ, Alverson MW. Outpatient second trimester pregnancy termination. Contraception. 2001;63:89–93
  31. Jain JK, Kuo J, Mishell DR. A comparison of two dosing regimens of intravaginal misoprostol for second-trimester pregnancy termination. Obstet Gynecol. 1999;93:571–575
  32. Leader J, Bujnovsky M, Carlan SJ, Triana T, Richichi K. Effect of oral misoprostol after second-trimester delivery: a randomized, blinded study. Obstet Gynecol. 2002;100:689–694
  33. Li CF, Chan CW, Ho PC. A study of the efficacy of cervical ripening with nitric oxide donor versus placebo for cervical priming before second-trimester termination of pregnancy. Contraception. 2003;68:269–272
  34. Menakaya U, Otoide V, Omo Agboja L, Odunsi K, Okonofua F. Experience with misoprostol in the management of missed abortion in the second trimester. J Obstet Gynaecol. 2005;25(6):583–585
  35. Munthali J, Moodley J. The use of misoprostol for mid-trimester therapeutic termination of pregnancy. Trop Doct. 2001;31:157–160
  36. Nuthalapaty FS, Ramsey PS, Biggio JR, Owen J. High-dose vaginal misoprostol versus concentrated oxytocin plus low-dose vaginal misoprostol for midtrimester labor induction: a randomized trial. Am J Obstet Gynecol. 2005;193:1065–1070
  37. Owen J, Hauth JC. Vaginal misoprostol versus concentrated oxytocin plus low-dose prostaglandin E2 for second trimester pregnancy termination. J Matern Fetal Med. 1999;8:48–50
  38. Ramsey PS, Savage K, Lincoln T, Owen J. Vaginal misoprostol versus concentrated oxytocin and vaginal PGE2 for second-trimester labor induction. Obstet Gynecol. 2004;104:138–145
  39. Yapar EG, Senöz S, Ürkütür M, Batioglu S, Gökmen O. Second trimester pregnancy termination including fetal death: comparison of five different methods. Eur J Obstet Reprod Biol. 1996;69:97–102
  40. Caliskan E, Dilbaz S, Doger E, Ozeren S, Dilbaz B. Randomized comparison of 3 misoprostol protocols for abortion induction at 13–20 weeks of gestation. J Reprod Med. 2005;50(3):173–180
  41. Chittacharoen A, Herabutya Y, Punyavachira P. A randomized trial of oral and vaginal misoprostol to manage delivery in cases of fetal death. Obstet Gynecol. 2003;101:70–73
  42. Fadalla FA, Mirghani OA, Adam I. Oral misoprostol versus vaginal misoprostol for termination of pregnancy with intrauterine fetal demise in the second-trimester. Int J Gynaecol Obstet. 2004;86:52–53
  43. Ghorab MNM, El Helw BA. Second-trimester termination of pregnancy by extra-amniotic prostaglandin F2 alfa or endocervical misoprostol. Acta Obstet Gynecol Scand. 1998;77:429–432
  44. Hidar S, Fekih M, Chaieb A, Bibi M, Mellouli R, Khairi H. Apport de l'association d'ocytocine au misoprostol administré en intravaginal au cours des interruptions de grossesses entre 13 et 29 semaines d'aménorrhée. Essai clinique prospectif randomisé. J Gynecol Obstet Biol Reprod. 2001;30:439–443
  45. Jain JK, Mishell DR. A comparison of intravaginal misoprostol with prostaglandin E2 for termination of second-trimester pregnancy. N Engl J Med. 1994;331:290–293
  46. Jain JJ, Mishell DR. A comparison of misoprostol with and without laminaria tents for induction of second-trimester abortion. Am J Obstet Gynecol. 1996;175:173–177
  47. Makhlouf AM, Al-Hussaini TK, Habib DM, Makarem MH. Second-trimester pregnancy termination: comparison of three different methods. J Obstet Gynecol. 2003;23(4):407–411
  48. Nakintu N. A comparative study of vaginal misoprostol and intravenous oxytocin for induction of labour in women with intra uterine fetal death in Mulago Hospital, Uganda. Afr Health Sci. 2001;1:55–59
  49. Niromanesh S, Hashemi-Fesharaki M, Mosavi-Jarrahi A. Second trimester abortion using intravaginal misoprostol. Int J Gynaecol Obstet. 2005;89:276–277
  50. Nyende L, Towobola OA, Mabina MH. Comparison of vaginal and oral misoprostol, for the induction of labour in women with intra-uterine foetal death. East Afri Med J. 2004;81:179–182
  51. Yilmaz B, Kelekci S, Ertas IE, Kahyaoglu S, Ozel M, Sut N, et al. Misoprostol moistened with acetic acid or saline for second trimester pregnancy termination: a randomized prospective double-blind trial. Hum Reprod. 2005;20(11):3067–3071
  52. Yilmaz B, Kelekci S, Ertas IF, et al. Randomized comparison of second trimester pregnancy termination utilizing saline moistened or dry misoprostol. Arch Gynecol Obstet. 2007;276:511–516

☆ No financial support was received for this report.

☆☆ Dr. Wing is a principal investigator for Cytokine PharmaSciences, developer of a time-released misoprostol vaginal insert.

PII: S0010-7824(08)00490-3

doi: 10.1016/j.contraception.2008.10.009

Contraception
Volume 79, Issue 4 , Pages 259-271 , April 2009

Article Tools

* Image Usage & Resolution